Loading the company…
Loading the company…
Families: CGM & insulin pump management.
All companies · Product and company coverage
In the last ten years FDA made 1 decision for Roche Diabetes Care (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 1 procedure family, the most in 2023 (1). The latest was on 2023-08-10.
| Family | Decisions on record |
|---|---|
| CGM & insulin pump management | 1 |
| Date | Kind | Number | Device |
|---|---|---|---|
| 2023-08-10 | 510(k) | K213134 | Accu-Chek Solo micropump system with interoperable technology |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Roche Diabetes Care.
In 2025, Roche Diabetes Care reported engagement with 2 surgeons and other clinicians in the states MedaRep covers, worth $23K in consulting, speaking, meals and travel for its device products, the most in California ($19K to 1). Royalties are left out.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: California ($19K, 1 engaged), Colorado ($3,750, 1 engaged).